An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)

Status:

UNKNOWN

An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Brief Summary

This prospective, multi-center observational study will assess the long-term efficacy and safety of RoActemra/Actemra in daily practice in patients with active moderate to severe rheumatoid arthritis ...

Eligibility Criteria

Inclusion

Adult patients, \>/= 18 years of age
Active moderate to severe rheumatoid arthritis
Inadequate response or intolerant to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists
Prescription of RoActemra/Actemra according to label

Exclusion

Key Trial Info

Start Date :

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

3404 Patients enrolled

Trial Details

Trial ID

NCT01194401

Last Update

November 2 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.